BCL2 and acute myeloid leukemia: Both Atg5FL and Atg5KO MLL-AF9-driven AML cells cultured in vitro were completely resistant to Bcl-2 and Bcl-xL inhibitors ABT-199 and ABT-737 (Table 1).30, 31 On the other hand, Atg5KO leukemic cells were sensitized to maritoclax, a small molecular antagonist of Mcl-1.32, 33, 34 We also observed a significant sensitization of Atg5KO leukemic cells to vorinostat, a histone deacetylase inhibitor, similar to previous findings.35